Vonvendi and Veyvondi market seen growing through 2035
The Business Research Company says the market for Vonvendi, also known as Veyvondi, is positioned for long-term growth as demand rises for recombinant therapies, home infusion and personalized rare-disease care. North America was the largest regional market in 2025, while the company’s new report looks at trends, forecasts and growth drivers through 2035.
Why it matters: - Vonvendi and Veyvondi are used to treat bleeding episodes in von Willebrand disease, so market growth tracks demand for care in a rare disorder with ongoing treatment needs. - The forecast points to broader adoption of recombinant, plasma-free therapies and more personalized hematology care. - The report highlights a commercial opportunity across hospital systems, specialty pharmacies and home infusion providers.
What happened: - The Business Research Company published its Vonvendi and Veyvondi Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says North America was the largest market for Vonvendi and Veyvondi in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company also promoted a free sample of the report and a full report download through its website.
The details: - Vonvendi, also known as Veyvondi, is a brand name for recombinant von Willebrand factor, or rVWF. - The treatment is used to control bleeding episodes in patients with von Willebrand disease by replacing missing or malfunctioning von Willebrand factor. - Historical growth was supported by more diagnoses of von Willebrand disease, greater availability of recombinant protein therapies, stronger clinical recognition of bleeding disorders, expansion of hospital hematology services and regulatory approvals of rVWF products. - Forecast growth is expected to be driven by personalized treatments for rare diseases, more investment in recombinant biologics, wider home-based infusion use, broader specialty pharmacy access and advances in protein engineering. - The report expects future trends to include wider use of recombinant plasma-free therapies, targeted treatments for bleeding disorders, on-demand bleeding management, expanded specialty pharmacy networks and more personalized hematology care. - A December 2024 Association of the British Pharmaceutical Industry report showed industry clinical trials rising from 411 in 2022 to 426 in 2023. - Pfizer reported in April 2025 that the UK haemophilia A and B patient population exceeded 11,800 in 2023/24. - The company said its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis.
Between the lines: - The report frames von Willebrand disease treatment as part of a wider shift toward precision medicine and outpatient care. - Rising clinical trial activity and greater disease awareness can support both physician adoption and payer confidence. - Specialty pharmacy distribution appears to be becoming more important as complex biologics move beyond traditional hospital-only administration.
What's next: - The market outlook extends through 2035, with growth expected to continue as recombinant therapies expand and care settings shift toward home use. - The Business Research Company is pushing buyers toward its sample report and full market report as the next step for deeper segmentation and competitive analysis. - The company invited prospects to contact its sales and marketing team for more information.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Consumer Products Africa
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.